Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting.

Neubauer MA, Hoverman JR, Kolodziej M, Reisman L, Gruschkus SK, Hoang S, Alva AA, McArthur M, Forsyth M, Rothermel T, Beveridge RA.

J Oncol Pract. 2010 Jan;6(1):12-8. doi: 10.1200/JOP.091058.

2.
3.

Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.

Brown T, Pilkington G, Bagust A, Boland A, Oyee J, Tudur-Smith C, Blundell M, Lai M, Martin Saborido C, Greenhalgh J, Dundar Y, Dickson R.

Health Technol Assess. 2013 Jul;17(31):1-278. doi: 10.3310/hta17310. Review. Erratum in: Health Technol Assess. 2015 May;17(31):281-2.

4.

Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting.

Shah M, Winfree KB, Peterson P, Gruschkus SK, Eaddy M, Green MR.

Lung Cancer. 2013 Oct;82(1):121-7. doi: 10.1016/j.lungcan.2013.07.021.

5.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

6.

Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.

Greenhalgh J, Bagust A, Boland A, Dwan K, Beale S, Hockenhull J, Proudlove C, Dundar Y, Richardson M, Dickson R, Mullard A, Marshall E.

Health Technol Assess. 2015 Jun;19(47):1-134. doi: 10.3310/hta19470. Review.

7.

Use of automated external defibrillators in cardiac arrest: an evidence-based analysis.

Health Quality Ontario..

Ont Health Technol Assess Ser. 2005;5(19):1-29.

8.

Rates of guideline adherence among US community oncologists treating NSCLC.

Wang Z, Askamit I, Tuscher L, Bergstrom K.

Am J Manag Care. 2013;19(3):185-92.

9.
10.

Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.

Stokes ME, Muehlenbein CE, Marciniak MD, Faries DE, Motabar S, Gillespie TW, Lipscomb J, Knopf KB, Buesching DP.

J Manag Care Pharm. 2009 Oct;15(8):669-82.

11.

Treatment Patterns and Health Resource Utilization Among Patients Diagnosed With Early Stage Resected Non-Small Cell Lung Cancer at US Community Oncology Practices.

Buck PO, Saverno KR, Miller PJ, Arondekar B, Walker MS.

Clin Lung Cancer. 2015 Nov;16(6):486-95. doi: 10.1016/j.cllc.2014.12.010.

12.

Cost-effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC.

Evans WK.

Oncology (Williston Park). 1998 Mar;12(3 Suppl 4):18-25; discussion 25-6.

13.

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.

Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G.

Health Technol Assess. 2001;5(28):1-110. Review.

14.

Cost-Effectiveness of Neoadjuvant Chemotherapy versus Primary Surgery in Elderly Patients with Advanced Ovarian Cancer.

Poonawalla IB, Lairson DR, Chan W, Piller LB, Du XL.

Value Health. 2015 Jun;18(4):387-95. doi: 10.1016/j.jval.2015.01.005.

15.

Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.

Plosker GL, Hurst M.

Pharmacoeconomics. 2001;19(11):1111-34. Review.

PMID:
11735678
16.

Cost-effectiveness of white blood cell growth factor use among a large nationwide cohort of elderly non-Hodgkin's lymphoma patients treated with chemotherapy.

Gruschkus SK, Lairson D, Dunn JK, Risser J, Du XL.

Value Health. 2011 Mar-Apr;14(2):253-62. doi: 10.1016/j.jval.2010.09.010.

18.
19.

Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy.

Khan I, Morris S, Hackshaw A, Lee SM.

BMJ Open. 2015 Jul 2;5(7):e006733. doi: 10.1136/bmjopen-2014-006733.

20.

Information technology facilitates cost-effectiveness analysis in developing countries: an observational study of breast cancer chemotherapy in Taiwan.

Shih YC, Pan IW, Tsai YW.

Pharmacoeconomics. 2009;27(11):947-61. doi: 10.2165/11314110-000000000-00000.

PMID:
19888794
Items per page

Supplemental Content

Support Center